High variability of COVID-19 case fatality rate in Germany

Matthias Wjst1,2* and Clemens Wendtner3

Abstract

Background During the first wave of the COVID-19 pandemic a high case fatality rate (CFR) was noticed worldwide including also Germany where the first European cases have been observed. The WHO recommended immediate intubation for patients with dyspnoea which has since been revised after reviewing the initial clinical outcome. The objective of this study is to analyze CFR and assess if there is an advantage of a more conservative management of COVID-19 induced hypoxemia.

Methods PCR confirmed COVID-19 infections and death counts were obtained for all German districts from 27 Jan 2020 until 15 Feb 2021 using official reports of Robert Koch Institute Berlin, Germany. A moving average CFRt was constructed by dividing disease related deaths two weeks after a given index day by the number of infections two weeks prior to that date. In addition to a local comparison also mortality outcomes in other German speaking countries were compared.

Results The mean CFR is estimated to be 2.92% based on 71,965 fatalities and 2,465,407 cases. There was a large regional scattering of CFRs across the German districts. Differences of the mortality pattern were observed also at state level and preserved across different sex and age groups while being largely independent of case numbers. Although Munich city had higher infection rates, more patients died during the first wave in Hamburg (OR 1.6, 95% CI 1.3–1.9) which was mirrored also by higher death risk at Hamburg intensive care units (OR 2.0, 95% CI 1.3–3.1). While the majority of Munich hospitals favoured a conservative management of hypoxemia including high flow nasal cannula (HFNC), Hamburg hospitals followed a more aggressive scheme of early mechanical ventilation (MV). Austria and Switzerland experienced higher CFRs than Germany during the first wave but after changing their treatment guidelines, both countries experienced lower CFRs during the second wave.

Conclusion Using retrospective public health data, different case fatality rates have been observed across Germany. A more conservative management of COVID-19 induced Adult Respiratory Distress Syndrome (ARDS) is justified also by epidemiological data.

Keywords COVID-19, Case fatality rate, High flow nasal cannula, Mechanical Ventilation, Munich, Hamburg, Germany

*Correspondence:[
Matthias Wjst
wjst@helmholtz-muenchen.de
1 Institut für Lungenbiologie (ILBD), Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Ingolstädter Landstr. 1, 85764 München-Neuherberg, Germany
2 Institut für KI und Informatik in der Medizin, Lehrstuhl für Medizinische Informatik, Klinikum rechts der Isar, Grillparzerstr. 18, 81675 München, Germany
3 München Klinik, Klinikum München Schwabing, Kölner Platz 1, 80804 München, Germany

© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
The COVID-19 pandemic wave started in Europe by the end of January 2020 [1]. While the initial cluster could be successfully contained [2, 3] the infection resurfaced only a month later in Bavaria (Germany), in the canton of Ticino (Switzerland) as well as in Tirol (Austria). An exceptional high case fatality rate (CFR) was observed at hotspots like Wuhan (China), Bergamo (Italy), and New York (US) [4]. An outbreak at the Diamond Princess cruise ship showed an age adjusted case fatality ratio as high as 2.6% (95% confidence interval (CI): 0.9–6.7) [5].

A high COVID-19 mortality has also been described in Germany at population level [6]. Another study, more from a clinical perspective examined 10.021 cases admitted to German hospitals. This study reported an in-hospital mortality of 22% and a huge variation depending on type of ventilation [7]. Both WHO and German guidelines recommended immediate intubation and mechanical ventilation (MV) as primary treatment of severe cases, although this recommendation was based on rather weak evidence [8]. As more than half of all patients died under MV, clinicians already in April 2020 raised doubts about the existing treatment guidelines.

Disease management has since undergone major changes. The discussion how COVID-19 related ARDS should be treated—either more aggressively by early intubation and MV or more conservatively by applying non-invasive ventilation (NIV) and high flow nasal cannula (HFNC) [9]—has since been under substantial debate. The objective of this study therefore is to further analyze CFR and possibly answer the question if there is an advantage of a more conservative management of COVID-19 induced hypoxemia.

Methods
The analysis relies on a COVID-19 surveillance project [1] that started after the identification of the first European case in Munich, Germany on Jan 27, 2020 and includes only laboratory confirmed disease reports. The end date for this analysis is 15 Feb 2021 just before the upsurge of the new variant B.1.1.7. and after the emergency use authorisation of the first vaccines in Germany by end of March 2020. Since the database was not fully functional before May 2020, only second wave data could be included here from www.datawrapper.de/_/wwQvR starting on Oct 31, 2020. Patient numbers of München hospitals were obtained from the local clinical management system (München Klinik Schwabing, TU München and LMU Koordination Pandemiemanagement) while data of Hamburg hospitals were retrieved from the literature [10] including the time interval 27 Jan 27 2020 until 3 June 2020. As PCR reagents had been temporarily exhausted, underreporting is being expected at some time points during the observation period.

The CFR is usually defined as the proportion of cases of a specified condition that are fatal within a specified time. This definition may lead to a paradox that more persons die of a disease than develop it during a given time period [11]. CFR therefore can be considered only final after the end of a pandemic although there maybe a need to calculate a CFRt even earlier as an evaluation parameter of interventions. Analogously to SIR infection models [12], CFRt has been constructed here by using a moving average where cases during the two weeks before the index day are summed and used as reference to all fatalities during the two weeks following the index day [13, 14]. Nevertheless, whenever infection rates fall too low, CFR values become unreliable high.

As the current analysis is neither preregistered nor does it include any sample size calculation, no P-values are reported in accordance to recent recommendations [15]. Instead graphical displays are used to describe the temporal trends [16–18] and whenever possible, 95% confidence intervals, have been included. R Version 3.6.3. was used along with Rstudio 1.3.1093 along with packages ggplot2, rgdal, ggmap, openxlsx, ggrepel, gmodels, MASS, dplyr, grid, gridExtra, rgeos, sp, sf, openxlsx, rjson, tidyrverse, stringr, magrittr and epitools. As mainly public data have been included, no ethical board has been involved. Nevertheless all methods were performed in accordance with the relevant ethical guidelines and local regulations.
Results

Germany is divided into 16 federal states (Fig. 1A insert) and 402 districts (Fig. 1A main figure). The CFR is estimated to be 2.92% based on 71,965 fatalities and 2,465,407 cases. Following some irregular high values at the beginning of the pandemic the CFRt dropped to more realistic values but increased again during the second wave (Fig. 1B and supplemental Figure). Although the peak CFRt was identical during both waves, there was a large number of high values during the first wave.
The highest CFR of all districts was observed in Sachsen / Görlitz including 957 deaths (CFR of 6.4%), followed by Thüringen / Suhl including 85 deaths (CFR of 6.4%) and Bayern / Schwabach including 100 deaths (CFR of 6.3%). There seems to be a considerable underreporting of PCR confirmed infections as described in later antibody studies [19] that might have led to inflated CFR estimates at least at the beginning of the first wave.

Since case counts were much higher during the second wave it may be interesting to look for a possible correlation of CFR and case count (Fig. 1D, for individual state figures see the supplement S1). Most states did not show any correlation, except for perhaps some weak increase in Lower Saxony, Rhineland-Palatinate and North Rhine-Westphalia, which could indicate capacity problems to deal with an increasing amount of patients. It may also be interesting to determine if there is a different age distribution by German states (Fig. 1E). The pattern is largely identical in all age groups, excluding any preferential effect on elderly people. Male sex is always leading to a higher CFR (Fig. 1F).

Figure 1G shows the relationship of CFR and MV patients at ICUs during the second wave in Germany. As there is no association at all, the high CFR variability depends on pre ICU conditions. This is shown in Fig. 1H where CFR steadily increases with the number of MV patients in relation to all COVID-19 infections in a district

In a further step the individual time course of the COVID-19 related CFR is compared between major German cities. Berlin is the largest city in Germany but had to be excluded here due to missing data for single districts. Interestingly, Hamburg and Munich, the second and third largest German cities with 1.8 and 1.6 million inhabitants (Fig. 2A) followed different treatment guidelines (Table 1). Although there are more cases in Munich due to the initial outbreak, death risk was found higher in Hamburg (OR 1.6; 1.3–1.9, Fig. 2B). According to official data by the Chamber of Physicians 2019, Hamburg has approximately 50% less physicians working in private praxis which correspond to a lower number of COVID-19 patients sent to hospitals (OR 0.7, 95% CI 0.7–0.8). Hamburg had also less physicians working on general wards which corresponds to a higher number of patients transferred to the ICU (OR 1.9, 95% CI 1.5–2.3). Hence, as also more cases are ventilated at ICUs in Hamburg, this is leading to a higher death rate (OR 2.0, 95% CI 1.3–3.1).

It may be interesting to set these results also in a European context. Germany ranked slightly higher than the EU average and considerably higher than Austria and Switzerland (Fig. 3A and B). Both countries experienced higher CFRs than Germany during the first wave (8 June 2020: Germany 1.3%, Switzerland 2.8%, Austria 4.9%) but after changing treatment guidelines, both countries had
lower CFRs during the second wave (2 December 2020: Germany 4.4%, Switzerland and Austria both 2.2%).

Discussion
COVID-19 related CFR became quickly a central outcome parameter in national and international reviews [20]. More in depth analysis of case fatalities nevertheless remained rare and are even difficult to interpret due to many influencing factors. We now find that the CFR in Germany exceeds not only EU average but also that of neighboring countries that had comparable age structure and health care systems.1

Already during the first wave Swiss clinics moved to intermediate care and administered respiratory support including HFNC and NIV) that prevented ICU admission for a large proportion of patients [21]. A rather similar development has been observed in Austria (C. Wenisch, pers comm). Both countries changed initial treatment strategies and, according to a recent press report, cancelled even the order of thousands of respirators that had been placed initially.2 This decision was not only based on local experience but also on new studies including a Canadian study that showed an increased hazard of death with each daily increment in driving pressure of mechanical ventilators [22]. Rather similar results were obtained in a Dutch study where the 28-day-mortality significantly increased with tidal volume [23].

In contrast, German CFRs remained high. This has been explained by different diagnostic thresholds whereas we do not find any consistent support for this view (Fig. 1D). Remarkably, the CFR is quite similar also in the younger age group which also argues against a higher affection of nursing homes or different prevalence of DNI/DNR orders. As most people die within hospitals [6] the main reason for the differences is primarily sought by different medical care where early intubation and MV may lead to a worse outcome. Overall ICU fatalities are lower than reported for Germany [6]. The reasons for the discrepancy are not fully clear—there may be some changes over time, there may be more patients dying at home or in nursing homes, there may be more case fatalities that are missed at non university hospitals. We may nevertheless estimate that up to 50% of hospital deaths during the first wave could have been avoided by more conservative treatment.

The exact numbers of ventilated patients have not been released so far. According to figures shown in [24] approximately 65% of ICU patients were ventilated in April during the peak of the first wave and about 55% during the peak of the second wave in December. The ICU outcome remained basically the same with 45% and 40% ICU patients dying in the first and second wave respectively [24]. The improvement in COVID-19 therapy therefore only depends on better initial clinical management as even transfer to ICU dropped from 30 to 14%.

A semi-ecological analysis like the one presented here may of course be influenced by various factors that could not be accounted for. Although consistent, some results may be distorted by improper definitions where standard, intermediate and intensive care are sometimes overlapping. Short-time MV may have different effects than long-time MV. Furthermore there are possible

---

1 https://www.reuters.com/article/us-health-coronavirus-ventilators-specialidUSkCN2251PE
2 https://www.nzz.ch/wirtschaft/schweiz-ploetzlich-zu-viele-beatmungsgeraete-id.1593268
confounding factors; regional outbreaks may inadvertently distort results or there might be different groups of the population being affected at different phases of the pandemic. There are also known issue with data quality and missing values. Although standardized and laboratory confirmed, the exact definition of COVID-19, associated death may vary between states, and there are known differences in SARS-COV2 testing capacity which all may have influenced both numerators and denominators.

Without doubt there are structural differences also between clinical departments where highly specialized centres with the capacity of ECMO therapy may get more seriously ill patients. To exclude that distortion the two second largest cities in Germany have been chosen as comparable units. TUM, where most patients have been treated in Munich, favoured a more conservative management of COVID-19 associated hypoxemia, while Hamburg clinics followed a more aggressive scheme of mechanical ventilation [10]. This may be concluded from numerous external and internal documents (Table 1) as NIV or HFNC is seen more as a bridging therapy in Hamburg clinics. Results obtained here underline the advantage of a less aggressive approach. The Munich approach originates from infectious diseases and pulmonology while Hamburg centers are more dominated by anaesthesiology. Patient centric NIV based therapy is also more demanding needing more personnel and experience to be applied correctly [25]. Although the ultimate goal of maintaining good oxygenation may be identical, fixed blood gas thresholds may be misleading in COVID-19 patients who have been described as "happy hypoxics" [26] as they can tolerate lower pO2 values than previously anticipated [27]. In the beginning of the pandemic, patients were also intubated not only in their own interest but also to reduce environmental virus contamination. Evidence is now accumulating that MV may have a negative effect of SARS-COV2 induced Acute Respiratory Distress Syndrome ARDS [28, 29].

Taken together, the results show a good agreement between the clinical and epidemiological findings [30] and provide further evidence that the high CFR in some German hospitals is caused by overtreatment [8, 31]. As randomized clinical trials are largely impossible, also routinely collected data [32] as being provided here, support the clinical observation that less invasive measures like HFNC can reduce the high CFR in ventilated COVID-19 patients. The current more conservative management therefore seems to be justified.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12889-023-15112-0.

Additional file 1: S1. Supplement to 1B. Time course of COVID-19 CFR in Germany broken down by state. S2. Supplement to 1D. Correlation of COVID-19 CFR in Germany broken down by state.

Acknowledgements
The author wants to thank Dres T. Voshaar, C. Staab-Weijnitz, S. Meiners, S. Dold and all participants and lecturers of the 2020/2021 LMU / HMGU Corona Infodemic seminar for helpful discussions. We wish to thank also M. Bonigut for providing hospital data, D. Bzowy for the snapshots of DIVI registry data and C. Oberschmidt for correction of the manuscript.
References

1. Wjst M. The early phase of the COVID-19 pandemic in Bavaria, Germany. Dtsch Med Wochenschr. 2021;146:e1–9.
2. Böhmer MM, Buchholz U, Corman VM, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. Lancet Infect Dis. 2020;20:920–8.
3. Wölfl R. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–9.
4. Potere N, Valeriani E, Candeloro M, et al. Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Crit Care. 2020;24:389.
5. Russell TW, Hellewell J, Jarvis CI, et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Eurosurveillance. 2020;25:200256.
6. Schilling J, Lehfeld A-S, Schumacher D, et al. Krankheitsverlauf der ersten COVID-19-Welle in Deutschland basierend auf den Meldungen gemäß Infektionsschutzgesetz. Journal of Health Monitoring. 2020;5:11–20.
7. Karagiannidis C, Mostert C, Hentschker C, et al. Case characteristics, resource use, and outcomes of 10,021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;8:PS3:862.
8. Tobin MJ, Joubert A, Laghi F. Misconceptions of pathophysiology of happy hypoxia and implications for management of COVID-19. Respir Res. 2020;21:249.
9. Oranber M, Gonzalez-Bermejo J, Daccosta-Noble P, et al. Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-control study. Eur Respir J. 2020;56:2001692.
10. Roedl K, Jarczak D, Thasler L, et al. Mechanical ventilation and mortality among 223 critically ill patients with coronavirus disease 2019: A multicentric study in Germany. Aust Crit Care. 2021;34:167–75.
11. Porta M, Greenland S, Hernán M, Silva IDS, Last JM. A dictionary of epidemiology. USA: Oxford University Press. 2014. p. 343.
12. Maier BF, Brockmann D. Effective containment explains subexponential growth in recent confirmed COVID-19 cases in China. Science. 2020;368:742–6.
13. Russell TW, Golding N, Hellewell J, et al. Reconstructing the early global dynamics of under-ascertained COVID-19 cases and infections. BMC Med. 2020;18:332.
14. Gianicolo E, Riccetti N, Blettner M, Karch A. Epidemiological measures in the context of the COVID-19 pandemic. Deutsches Ärzteblatt Int. 2020;117:336–42.
15. Wasserstein RL, Schirm AL, Lazar NA. Moving to a world beyond “p < 0.05”. The American Statistician. 2019;73:1–19.
16. Anscombe FJ. Graphs in statistical analysis. Am Stat. 1973;27:17–21.
17. Tukey JW. The visual display of quantitative information. 1983. p. 197.
18. Tukey JW. Sunset salvo. Am Stat. 1986;40:72–6.
19. Hippich M, Sift P, Zapardiel-Gonzalo J, et al. A Public Health Antibody Screening Indicates a Marked Increase of SARS-CoV-2 Exposure Rate in Children during the Second Wave. Med. 2021;14(2):571–2.
20. Tian W, Jiang W, Yao J, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2020;92:1875–83.
21. Grosgurin O, Leidi A, Farhoumand PO, et al. Role of intermediate care unit admission and non-invasive respiratory support during the COVID-19 pandemic: a retrospective cohort study. Respir. 2021;100:786–93.
22. Umer M, Jüni P, Hansen B, Wettstein MS, Ferguson ND, Fan E. Time-varying intensity of mechanical ventilation and mortality in patients with acute respiratory failure: a registry-based, prospective cohort study. Lancet Respir Med. 2020;8:905–13.
23. Bott M, Tsonias AM, Pillay J, et al. Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PROVENT-COVID): a national, multicentre, observational cohort study. Lancet Respir Med. 2021;9:139–48.
24. Karagiannidis C, Windisch W, McAuley DF, Welte T, Busse R. Major differences in ICU admissions during the first and second COVID-19 wave in Germany. Lancet Respir Med. 2021;9:e47–8.
25. Tobin MJ. Noninvasive strategies in COVID-19: epistemology, randomised trials, guidelines, physiology. Eur Respir J. 2021;57:2004247.
26. Couzin-Frankel J. The mystery of the pandemic’s happy hypoxia. Science. 2020;368:455–6.
27. Schömig OL, Kliptgaard TL, Perner A, et al. Lower or higher oxygenation targets for acute hypoxic respiratory failure. N Engl J Med. 2021;384:1301–11.
28. Becher T, Frerichs I. Mortality in COVID-19 is not merely a question of resource availability. Lancet Respir Med. 2020;9:832–3.
29. Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020;8:518–26.
30. Lipitch M, Swordlow DL, Finelli L. Defining the epidemiology of Covid-19 — Studies needed. N Engl J Med. 2020;382:1194–6.
31. Voshaar T, Stais P, Köhler D, Dellweg D. Conservative management of Covid 19 associated hypoxemia. ERJ Open Res. 2021;7:00134—Studies needed. N Engl J Med. 2020;382:1194–6.
32. Tukey JW. The mystery of the pandemic’s happy hypoxia. Science. 2020;368:455–6.
33. Anscombe FJ. Graphs in statistical analysis. Am Stat. 1973;27:17–21.
34. Schjørring OL, Klitgaard TL, Perner A, et al. Lower or higher oxygenation targets for acute hypoxic respiratory failure. N Engl J Med. 2021;384:1301–11.
35. Becher T, Frerichs I. Mortality in COVID-19 is not merely a question of resource availability. Lancet Respir Med. 2020;9:832–3.
36. Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med. 2020;8:518–26.
37. Lipitch M, Swordlow DL, Finelli L. Defining the epidemiology of Covid-19 — Studies needed. N Engl J Med. 2020;382:1194–6.
38. Voshaar T, Stais P, Kohler D, Dellweg D. Conservative management of Covid 19 associated hypoxemia. ERJ Open Res. 2021;7:00134—Studies needed. N Engl J Med. 2020;382:1194–6.
39. Tukey JW. The mystery of the pandemic’s happy hypoxia. Science. 2020;368:455–6.
40. Voshaar T, Stais P, Kohler D, Dellweg D. Conservative management of Covid 19 associated hypoxemia. ERJ Open Res. 2021;7:00134—Studies needed. N Engl J Med. 2020;382:1194–6.
41. Tukey JW. The mystery of the pandemic’s happy hypoxia. Science. 2020;368:455–6.